COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

Monoclonal antibodies show great promise in treating Covid-19 patients. Here, Maisonnasse, Aldon and colleagues report pre-clinical results for COVA1-18 and demonstrate that it reduces viral infectivity in three animal models with over 95% efficacy in macaques upper respiratory tract.

Bibliographic Details
Main Authors: Pauline Maisonnasse, Yoann Aldon, Aurélien Marc, Romain Marlin, Nathalie Dereuddre-Bosquet, Natalia A. Kuzmina, Alec W. Freyn, Jonne L. Snitselaar, Antonio Gonçalves, Tom G. Caniels, Judith A. Burger, Meliawati Poniman, Ilja Bontjer, Virginie Chesnais, Ségolène Diry, Anton Iershov, Adam J. Ronk, Sonia Jangra, Raveen Rathnasinghe, Philip J. M. Brouwer, Tom P. L. Bijl, Jelle van Schooten, Mitch Brinkkemper, Hejun Liu, Meng Yuan, Chad E. Mire, Mariëlle J. van Breemen, Vanessa Contreras, Thibaut Naninck, Julien Lemaître, Nidhal Kahlaoui, Francis Relouzat, Catherine Chapon, Raphaël Ho Tsong Fang, Charlene McDanal, Mary Osei-Twum, Natalie St-Amant, Luc Gagnon, David C. Montefiori, Ian A. Wilson, Eric Ginoux, Godelieve J. de Bree, Adolfo García-Sastre, Michael Schotsaert, Lynda Coughlan, Alexander Bukreyev, Sylvie van der Werf, Jérémie Guedj, Rogier W. Sanders, Marit J. van Gils, Roger Le Grand
Format: Article
Language:English
Published: Nature Portfolio 2021-10-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-26354-0

Internet

https://doi.org/10.1038/s41467-021-26354-0

Similar Items